AMENDMENT

In the Claims

Please note amendments relative to the invention as claimed as follow:

1. (currently amended) A compound ~~product~~ of general formula



(I)

in which:

R_1 represents ~~the~~ a stereoisomeric ~~forms~~ form of the chain

$-(CHOH)_3-CH_2-O-COR$ (II),

~~and~~

~~either~~ R_2 represents a hydrogen atom and R_3 represents ~~the~~ a stereoisomeric ~~forms~~ form of the chain

$-CH_2-(CHOH)_2-CH_2-O-COR$ (III)

or R_2 represents ~~the~~ a stereoisomeric ~~forms~~ form of the chain ~~chains~~

$-(CHOH)_3-CH_2-O-COR$ (II)

or

$-CH_2-(CHOH)_2-CH_2-O-COR$ (III),

~~and~~ R_3 represents a hydrogen atom,

~~and~~

R represents an -(Alk)i-(Cycloalk) radical,

for which:

Alk denotes an alkyl radical that means a saturated straight- or branched-chain hydrocarbonaceous radical comprising 1 to 6 carbon atoms,

Cycloalk denotes a cycloalkyl radical that means a saturated cyclic hydrocarbonaceous radical comprising 5 or 6 carbon atoms, and

i is equal to 0 or 1;

or

a stereoisomeric form thereof or pharmaceutically acceptable salt thereof with an inorganic or organic acid.

2. (currently amended) The compound ~~product~~ according to Claim 1of general formula (IV), (V) or (VI):



(IV)



(V)



(VI),

in which

R represents an -(Alk)i-(Cycloalk) radical,

for which:

Alk denotes an alkyl radical that means a saturated straight- or branched-chain hydrocarbonaceous radical comprising 1 to 6 carbon atoms,

Cycloalk denotes a cycloalkyl radical that means a saturated cyclic hydrocarbonaceous radical comprising 5 or 6 carbon atoms, and

i is equal to 0 or 1;

or

a stereoisomeric form thereof or pharmaceutically acceptable salt thereof with an inorganic or organic acid.

3. (currently amended) A compound ~~product~~ according to ~~the preceding claim~~ Claim 1 of general formula (VII), (VIII) or (IX):



(VII)



(VIII)



(IX)

in which

R represents an -(Alk)i-(Cycloalk) radical,

for which:

Alk denotes an alkyl radical that means a saturated straight- or branched-chain hydrocarbonaceous radical comprising 1 to 6 carbon atoms,

Cycloalk denotes a cycloalkyl radical that means a saturated cyclic hydrocarbonaceous radical comprising 5 or 6 carbon atoms, and

i is equal to 0 or 1;

or

a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

4. (currently amended) The compound ~~A product~~ according to Claim 1 ~~the preceding claim~~ of general formula (IX):



(IX)

in which:

R represents an -(Alk)i-(Cycloalk) radical,

for which:

Alk denotes an alkyl radical that means a saturated straight- or branched-chain hydrocarbonaceous radical comprising 1 to 6 carbon atoms,

Cycloalk denotes a cycloalkyl radical that means a saturated cyclic hydrocarbonaceous radical comprising 5 or 6 carbon atoms, and

i is equal t 0 or 1;

or

a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

5. (currently amended) The compound ~~A product~~ according to ~~claim~~ Claim 1 for which:

R represents an -(Alk)i-(Cycloalk) radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical, and

i is equal to 0 or 1;

or

a stereoisomeric form thereof or pharmaceutically acceptable salt thereof with an inorganic or organic acid.

6. (currently amended) The compound ~~A product~~ according to ~~claim~~ Claim 2 for which:

R represents an -(Alk)i-(Cycloalk) radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical, and

i is equal to 0 or 1;

or

a stereoisomeric form thereof or pharmaceutically acceptable salt thereof with an inorganic or organic acid.

7. (currently amended) The compound ~~A product~~ according to ~~claim~~ Claim 3 for which:

R represents an -(Alk)i-(Cycloalk) radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical, and

i is equal to 0 or 1;

or

a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

8. (currently amended) The compound ~~A product~~ according to ~~claim~~ Claim 4 for which:

R represents an -(Alk)i-(Cycloalk) radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical, and

i is equal to 0 or 1;

or

a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

9. (currently amended) The compound ~~A product~~ according to ~~claim~~ Claim 1 which is ~~selected from the group consisting of:~~

4,4'-O,O-dicyclohexyloyl-2-[(1R,2S,3R)(1,2,3,4-tetrahydroxylbutyl)]-5-[(2'S,3'R)(2',3',4'-trihydroxy-butyl)]pyrazine, ~~and~~ or

4,4'-O,O-di(cyclohexylacetyl)-2-[(1R,2S,3R)(1,2,3,4-tetrahydroxylbutyl)]-5-[(2'S,3'R)-(2',3',4'-trihydroxybutyl)]pyrazine,

or

a pharmaceutically acceptable salt thereof with an inorganic or organic acid.

10. (currently amended) The compound according to Claim 1 which is 4,4'-O,O-Dicyclohexyloyl-2-[(1R,2S,3R)(1,2,3,4-tetrahydroxylbutyl)]-5-[(2'S,3'R)(2',3',4'-trihydroxybutyl)]pyrazine,

or

a pharmaceutically acceptable salt thereof ~~and its salts~~ with an inorganic or organic acid.

11. (currently amended) A process for the preparation of the compound ~~product~~ according to Claim ~~claim~~ 1, comprising reacting a compound ~~product~~ of general formula:



(X)

in which:

Ri1 represents a stereoisomeric form of the chain

$-(CHOH)_3-CH_2OH$ (XI),

~~and~~

Ri2 represents a hydrogen atom and Ri3 represents a stereoisomeric form of the chain

$-CH_2-(CHOH)_2-CH_2OH$ (XII)

or

Ri2 represents ~~the~~ a stereoisomeric ~~forms~~ form of the chain ~~chains~~

$-(CHOH)_3-CH_2OH$ (XI)

or

$-CH_2-(CHOH)_2-CH_2OH$ (XII),

and Ri3 represents a hydrogen atom,

with an acyl halide of formula R-COX, in which R is defined as in Claim 1 and X represents a halogen atom.

12. (original) The process according to Claim 11, wherein the reaction is carried out in the presence of pyridine between 0 and 40°C.

13. (currently amended) A pharmaceutical composition ~~medicament~~ comprising ~~as active principle~~ a pharmaceutically appropriate dosage of a compound ~~product~~ according to Claim ~~claim~~ 1 and ~~an~~ a pharmaceutically compatible excipient.

14. (canceled)

15. (new) A method of preventing or treating glycemia in a human comprising administering to the human a pharmaceutically appropriate dosage of the compound of Claim 1.